 | Up a level |
Tamargo, J; Kjeldsen, K P; Delpón, E; Semb, A G; Cerbai, E; Dobrev, D; Savarese, G; Sulzgruber, P; Rosano, G; Borghi, C; Wassman, S; Torp-Pedersen, C T; Agewall, S; Drexel, H; Baumgartner, I; Lewis, B S; Ceconi, C; Kaski, J C; Niessner, A (2022). Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European heart journal. Cardiovascular pharmacotherapy, 8(4), pp. 406-419. Oxford University Press 10.1093/ehjcvp/pvac005
Catapano, A; Reiner, Z; De Backer, G; Graham, I; Taskinen, M; Wiklund, O; Agewall, S; Alegria, E; Chapman, M; Durrington, P; Erdine, S; Halcox, J; Hobbs, R; Kjekshus, J; Filardi, P; Riccardi, G; Storey, R; Wood, D; incl. Windecker S, (2011). Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis, 217(1), pp. 3-46. Amsterdam: Elsevier 10.1016/j.atherosclerosis.2011.06.028
